TrxR2 Lactylation Facilitates Mitochondrial Protection and Endothelial Ferroptosis Resistance in Diabetic Cardiomyopathy
Advanced Science · 2026-04 · 13 (22)
DOI: 10.1002/advs.202521997 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 17.02.2026. Verfasst von Su Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai, P. R. China. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies, Ferroptosis, Thioredoxin Reductase 2, Mitochondria. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Scientific Research Project of the Gusu Health Talent Plan.
Abstract (Originalsprache)
Thioredoxin reductase 2 (TrxR2), a radical‐trapping antioxidant, plays a critical role in cardiac defense. However, the mechanisms underlying its benefits remain unclear. In this study, we aimed to investigate whether endothelial TrxR2 prevents cardiac microvascular dysfunction in diabetic cardiomyopathy (DCM). Key genes in the thioredoxin family and those involved in ferroptosis were analyzed using bulk RNA‐sequencing assay. Diabetic injury was induced in multiple transgenic mouse models, including endothelial cell‐specific knockout mice for TrxR2, sterol carrier protein 2 (SCP2), and Tu translation elongation factor, mitochondrial (TUFM). The TrxR2 lactylation site was identified by mass spectrometry and verified by a custom‐made lactylation antibody. Mitochondrial thioredoxin reductase (mitoTrxR) activity and lipid peroxyl radicals were detected using fluorescence staining. Endothelial TrxR2 deficiency significantly suppressed mitoTrxR activity, exacerbated cardiac microvascular dysfunction, and accelerated DCM progression. In contrast, TrxR2 overexpression and Kukoamine B (TrxR2 agonist) treatment inhibited mitochondria‐associated ferroptosis by facilitating SCP2 degradation and blocking the mitochondrial translocation of acyl‐CoA synthetase long‐chain family member 4 (ACSL4) via mitophagy. Mechanistically, TrxR2 maintained TUFM expression by scavenging oxygen radicals, thereby facilitating the mitochondrial translocation of AMPK for mitophagy activation. TrxR2 undergoes lactylation at lysine 340. This process is mediated by mitochondrial alanyl‐tRNA synthetase 2 (AARS2) and lactate accumulation in both human and mouse diabetic hearts. This modification and sodium lactate administration compensatorily enhanced mitoTrxR activity, promoted mitophagy, and conferred ferroptosis resistance in cardiac microcirculation in DCM. Our findings demonstrate that TrxR2 and its lactylation modification promote mitophagy, enhance ferroptosis resistance, and improve cardiac microvascular function in DCM. Thus, this study provides a promising therapeutic approach for the management of diabetic complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Zhongshan Hospital, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai, P. R. China.
- Department of Cardiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Suzhou, P. R. China.
- Center for Precision Cancer Medicine & Translational Research, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tia…
- Department of Respiratory Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Suzhou, P. R. China.
- Ministry of Science and Technology, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, P. R. China.
- XuZhou Clinical School of Xuzhou Medical University, Department of Cardiology, Xuzhou Central Hospital, XuZhou Institute of Cardiovascular disease, Xuzhou, P. R. China.
ORCID-Profile: Yuqiong Chen
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Scientific Research Project of the Gusu Health Talent Plan
- Nanjing Medical University Science and Technology development project
- Suzhou Science and Technology Innovation Project
- Natural Science Foundation of Jiangsu Province
- Science and Technology Talent Trusted Project of Jiangsu Province
- Tianjin Key Medical Discipline Construction Project
Zitieren
APA
Li, S., Liu, M., Chen, C., Li, X., Yan, X., Zhu, W., Qiu, W., Li, Q., Sun, X., Huang, C., Yin, M., Chen, Z., Lu, Y., Ge, J., Kong, X., Qian, J., & Chen, Y. (2026). TrxR2 Lactylation Facilitates Mitochondrial Protection and Endothelial Ferroptosis Resistance in Diabetic Cardiomyopathy. Advanced Science, 13(22). https://doi.org/10.1002/advs.202521997
Vancouver
Li S, Liu M, Chen C, Li X, Yan X, Zhu W, et al. TrxR2 Lactylation Facilitates Mitochondrial Protection and Endothelial Ferroptosis Resistance in Diabetic Cardiomyopathy. Advanced Science. 2026;13(22). doi:10.1002/advs.202521997
BibTeX
@article{Li2026,
author = {Li, Su and Liu, Muyin and Chen, Chao and Li, Xinyan and Yan, Xiaopei and Zhu, Wentao and Qiu, Wenyan and Li, Qiyu and Sun, Xiangyu and Huang, Chao and Yin, Ming and Chen, Zhangwei and Lu, Yao and Ge, Junbo and Kong, Xiangqing and Qian, Juying and Chen, Yuqiong},
title = {TrxR2 Lactylation Facilitates Mitochondrial Protection and Endothelial Ferroptosis Resistance in Diabetic Cardiomyopathy},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {22},
doi = {10.1002/advs.202521997}
}
EUVIMED